#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure

MUNICH — Novartis is to kick off a Phase 3 trial to see whether its anti–IL‑6 antibody can prevent cardiovascular (CV) events in people with elevated CV risk by reducing inflammation, despite the failure of ...